[go: up one dir, main page]

ZA200903134B - Modified soluble FGF receptor FC fusions with improved biological activity - Google Patents

Modified soluble FGF receptor FC fusions with improved biological activity

Info

Publication number
ZA200903134B
ZA200903134B ZA200903134A ZA200903134A ZA200903134B ZA 200903134 B ZA200903134 B ZA 200903134B ZA 200903134 A ZA200903134 A ZA 200903134A ZA 200903134 A ZA200903134 A ZA 200903134A ZA 200903134 B ZA200903134 B ZA 200903134B
Authority
ZA
South Africa
Prior art keywords
fusions
biological activity
fgf receptor
improved biological
modified soluble
Prior art date
Application number
ZA200903134A
Inventor
Mark Nesbit
Beatrice Cameron
Francis Blanche
Sylvie Sordello
Celine Nicolazzi
Marc Trombe
Original Assignee
Centelion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centelion filed Critical Centelion
Publication of ZA200903134B publication Critical patent/ZA200903134B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/32Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200903134A 2006-11-28 2007-11-28 Modified soluble FGF receptor FC fusions with improved biological activity ZA200903134B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06291824 2006-11-28

Publications (1)

Publication Number Publication Date
ZA200903134B true ZA200903134B (en) 2010-08-25

Family

ID=37908084

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200903134A ZA200903134B (en) 2006-11-28 2007-11-28 Modified soluble FGF receptor FC fusions with improved biological activity

Country Status (5)

Country Link
CN (1) CN101589145B (en)
DO (1) DOP2009000115A (en)
ES (1) ES2366160T3 (en)
UY (1) UY30749A1 (en)
ZA (1) ZA200903134B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6178240B2 (en) * 2010-11-15 2017-08-09 ファイブ プライム セラピューティックス インコーポレイテッド Treatment of cancer with high doses of soluble FGFR1 fusion protein
CN102219860B (en) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 FGFR-Fc fusion protein and applications thereof
CA2880013C (en) * 2012-07-24 2022-11-29 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
US9957313B2 (en) 2013-03-15 2018-05-01 Remegen, Ltd. FGFR-FC fusion proteins and the use thereof
EP3380523A1 (en) * 2015-11-23 2018-10-03 Five Prime Therapeutics, Inc. Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000046380A2 (en) * 1999-02-08 2000-08-10 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion

Also Published As

Publication number Publication date
CN101589145A (en) 2009-11-25
UY30749A1 (en) 2008-07-03
ES2366160T3 (en) 2011-10-17
DOP2009000115A (en) 2010-02-15
CN101589145B (en) 2013-11-13

Similar Documents

Publication Publication Date Title
IL198480A0 (en) Modified soluble fgf receptor fc fusions with improved biological activity
EP2214700A4 (en) Semi-synthetic glp-1 peptide-fc fusion constructs, methods and uses
PL2173381T3 (en) Fc receptor-binding polypeptides with modified effector functions
EP3184546B8 (en) Human cgrp receptor binding antibodies
EP2367793B8 (en) Gpr120 receptor agonists and uses thereof
EP2077757A4 (en) Means for sampling animal blood
EP2313435A4 (en) Fibroblast growth factor receptor 3 (fgfr3) binding proteins
EP2032812A4 (en) Diesel catalyst system
SI2303891T1 (en) Pyrazolo-quinazolines as protein kinase activity modulators
ZA200809972B (en) Catalysts
GB0603501D0 (en) Catalyst
GB0707129D0 (en) Fermenter monitor
EP2000201A4 (en) Catalyst composition
IL205749A0 (en) Modified il-4 mutein receptor antagonists
EP1984862A4 (en) Plasmon tomography
ZA200903134B (en) Modified soluble FGF receptor FC fusions with improved biological activity
GB0901092D0 (en) Pyrrole derivatives with crth2 rececptor modulator activity
ZA201000215B (en) Sequential enzyme delivery system
IL197033A0 (en) Single use self-disabling syringe
ZA200809732B (en) Single use syringe
GB0914192D0 (en) Activity monitor with incentive features
AU2006905670A0 (en) Animal warming system
AU2006905749A0 (en) Animal warming system
DE602007006839D1 (en) PEGYLATED PTH AS PTH RECEPTOR MODULATORS AND THEIR USE
PL380823A1 (en) The manner system for fillof cylinders with medical oxygen